The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy research assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research.
Features and Benefits Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3 Includes reagents, bioinformatics and software Streamlined, end-to-end research workflow from extraction to analysis and reporting in five days
USDEnglish
TRYTurkish
Request a Meeting
